[Efforts in the individualization of the adjuvant systemic therapy in breast cancer--ASCO, 2004].
Kahán
Zsuzsanna
Z
Szegedi Tudomanyegyetem, Onkoterápiás Klinika, Szeged, Hungary.
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D000077289:Letrozole; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009570:Nitriles / Q000008:administration & dosage; D010347:Patient Care Planning / Q000592:standards*; D017060:Patient Satisfaction; D018579:Patient Selection; D011237:Predictive Value of Tests; D011788:Quality of Life; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D013629:Tamoxifen / Q000008:administration & dosage; D014230:Triazoles / Q000008:administration & dosage
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D000077289:Letrozole; D009570:Nitriles; D018719:Erb-b2 Receptor Tyrosine Kinases; D013629:Tamoxifen; D014230:Triazoles